-
EP2190881
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2190881
| EP2190881 - ANTI-IDIOTYPIC ANTIBODIES WHICH NEUTRALISE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST THE C1 DOMAIN OF FACTOR VIII [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.08.2013 Database last updated on 02.11.2024 | Most recent event Tooltip | 02.08.2013 | Application deemed to be withdrawn | published on 04.09.2013 [2013/36] | Applicant(s) | For all designated states LFB Biotechnologies ZA de Courtaboeuf 3 Avenue des Tropiques 91940 Les Ulis / FR | [2010/22] | Inventor(s) | 01 /
GILLES, Jean-Guy Avenue de l'Exposition 410/bte 51 B-1090 Bruxelles / BE | 02 /
JACQUEMIN, Marc, G. Rue Morimont 45 B-5330 Sart-Bernard / BE | 03 /
SAINT-REMY, Jean-Marie Rue de Lambais 79 B-1390 Grez-Doiceau / BE | 04 /
BEHRENS, Christian 10 ancien chemin de Villaine F-91120 Palaiseau / FR | [2010/22] | Representative(s) | Hirsch & Associés 154 Boulevard Haussmann 75008 Paris / FR | [N/P] |
| Former [2010/22] | Hirsch & Associés 58, Avenue Marceau 75008 Paris / FR | Application number, filing date | 07823446.5 | 23.08.2007 | [2010/22] | WO2007FR01398 | Filing language | FR | Procedural language | FR | Publication | Type: | A1 Application with search report | No.: | WO2009024653 | Date: | 26.02.2009 | Language: | FR | [2009/09] | Type: | A1 Application with search report | No.: | EP2190881 | Date: | 02.06.2010 | Language: | FR | The application published by WIPO in one of the EPO official languages on 26.02.2009 takes the place of the publication of the European patent application. | [2010/22] | Search report(s) | International search report - published on: | EP | 26.02.2009 | Classification | IPC: | C07K16/42, A61K39/395, C12N15/13, C12N5/20, A61P7/04, G01N33/53 | [2010/22] | CPC: |
C07K16/4241 (EP);
A61P7/04 (EP);
A61K2039/505 (EP);
C07K2317/56 (EP);
C07K2317/565 (EP);
C07K2317/76 (EP);
C07K2317/92 (EP)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2010/22] | Title | German: | ANTIIDIOTYPISCHE ANTIKÖRPER, DIE DIE INHIBITORISCHE AKTIVITÄT EINES GEGEN DIE C1-DOMÄNE VON FAKTOR VIII GERICHTETEN INHIBIERENDEN ANTIKÖRPERS NEUTRALISIEREN | [2010/22] | English: | ANTI-IDIOTYPIC ANTIBODIES WHICH NEUTRALISE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST THE C1 DOMAIN OF FACTOR VIII | [2010/22] | French: | ANTICORPS ANTI-IDIOTYPIGUES NEUTRALISANT L'ACTIVITE INHIBITRICE D'UN ANTICORPS INHIBITEUR DIRIGE CONTRE LE DOMAINE C1 DU FACTEUR VIII | [2010/22] | Biological material | This application mentions deposited biological material, check the file for details | Entry into regional phase | 23.03.2010 | National basic fee paid | 23.03.2010 | Designation fee(s) paid | 23.03.2010 | Examination fee paid | Examination procedure | 23.03.2010 | Amendment by applicant (claims and/or description) | 23.03.2010 | Examination requested [2010/22] | 07.12.2012 | Despatch of a communication from the examining division (Time limit: M04) | 01.03.2013 | Application deemed to be withdrawn, date of legal effect [2013/36] | 09.04.2013 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2013/36] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 07.12.2012 | Fees paid | Renewal fee | 23.03.2010 | Renewal fee patent year 03 | 31.08.2010 | Renewal fee patent year 04 | 31.08.2011 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.08.2012 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP1749537 (LAB FRANCAIS DU FRACTIONNEMENT [FR]) [Y] 1-23 * abstract *; | [Y]EP1388544 (D COLLEN RES FOUNDATION VZW [BE]) [Y] 1-23 * abstract *; | [DY]WO2005016455 (D COLLEN RES FOUNDATION VZW [BE], et al) [DY] 1-23 * example 12; sequences 29-32 *; | [E]WO2007096536 (LAB FRANCAIS DU FRACTIONNEMENT [FR], et al) [E] 1-23 * the whole document *; | [E]FR2897868 (LAB FRANCAIS DU FRACTIONNEMENT [FR]) [E] 1-23 * Identique à la présente demande.;; claims 1-29 * | [Y] - GILLES JEAN GUY G ET AL, "A limited number of anti-idiotypic antibodies is required to maintain FVIII function in presence of polyclonal anti-FVIII antibodies of haemophilia a patients with inhibitors.", BLOOD, & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, (200611), vol. 108, no. 11, Part 1, ISSN 0006-4971, page 299A, XP009099673 [Y] 1-23 * the whole document * | [Y] - GILLES JEAN GUY G ET AL, "In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody", BLOOD, (20040401), vol. 103, no. 7, ISSN 0006-4971, pages 2617 - 2623, XP002479159 [Y] 1-23 * abstract * DOI: http://dx.doi.org/10.1182/blood-2003-07-2207 | [A] - PIPE S W ET AL, "New high-technology products for the treatment of haemophilia", HAEMOPHILIA, BLACKWELL SCIENCE, OXFORD, GB, (20041001), vol. 10, no. SUPPL 4, ISSN 1351-8216, pages 55 - 63, XP002404355 [A] * page 58, column R, paragraph 2 - page 59, column L, paragraph 1 * |